Kinnov-Therapeutics

Kinnov Therapeutics is a biopharmaceutical company dedicated to developing innovative therapies for addiction. Backed by scientists with extensive experience in drug discovery and development, we have identified key receptors involved in addiction. KT-110, our first-in-class lead compound, has entered Phase 2 clinical trials for alcohol addiction.